RESEARCH TRIANGLE PARK, N.C. and Boston, Mass. — August 4, 2026 —Westbridge Clinical Ltd, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.
The collaboration brings together Westbridge Clinical’s global clinical trial and commercialization infrastructure with Medera’s pioneering platforms: Sardocor, focused on developing disease-modifying gene therapies for difficult-to-treat cardiovascular diseases, and Novoheart, a leader in engineered human-based cardiac tissue for disease modelling and drug screening.
Sardocor will leverage Westbridge Clinical’s regulatory and trial execution expertise to advance its FDA-cleared, first-in-human AAV-based gene therapy programs. Westbridge Clinical will support patient recruitment, data quality and regulatory filings, including applications for expedited FDA designations.
Novoheart’s mini-Heart platform is already instrumental in securing IND and Fast Track designations and offers a predictive, human-based alternative to animal testing. The platform is expanding into multiple organ systems to support drug discovery and safety testing under the FDA Modernization Act 2.0.
“By combining Westbridge Clinical’s global expertise with Medera’s mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster,” said Ronald Li, Co-Founder, Chairman & CEO of Medera. “This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation.”
About Westbridge Clinical
Westbridge Clinical Ltd is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Westbridge Clinical’s portfolio of solutions are powered by Westbridge Clinical Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. Westbridge Clinical is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, Westbridge Clinical is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.